Reuters Market Eye - Shares in Ranbaxy Laboratories Ltd up as much as 2.2 percent after Business Standard reports the company has partnered with an unnamed multinational drug maker to procure API, or active pharmaceutical ingredient, for a generic version of an anti-hypertension drug, citing unnamed sources.
Ranbaxy declines to comment on the media report
HSBC notes that sourcing API could potentially mean reduced profits for Ranbaxy, but would help increase confidence on cash flow generation.
Ranbaxy shares fell sharply on Monday and Tuesday after the company said U.S. FDA had raised concerns about manufacturing practices at one of its factories.
The stock was flat in trade at 2.58 p.m.
(Reporting by Indulal PM)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app